Combined treatment with a TLR7 agonist and an HBV capsid assembly inhibitor
US11771699B2 · kind B2 · utility
0Cited by
15References
32Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 15, 2017 |
| Grant date | Oct 3, 2023 |
| Priority date | — |
| Expiry date | Sep 15, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2300/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to compositions and methods for treating hepatitis B virus infection. In particular, the present invention is directed to a combination therapy comprising administration of a TLR7 agonist and an HBV capsid assembly inhibitor for use in the treatment of chronic hepatitis B patient.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.